Increasing plasma glucose before the development of type 1 diabetes-the TRIGR study.
Autoantibodies
/ blood
Blood Glucose
/ analysis
Cohort Studies
Diabetes Mellitus, Type 1
/ blood
Double-Blind Method
Female
Follow-Up Studies
Genetic Predisposition to Disease
Glycated Hemoglobin
/ analysis
HLA Antigens
/ genetics
Humans
Infant
Insulin
/ physiology
Insulin Resistance
/ physiology
Insulin-Secreting Cells
/ immunology
Male
Stress, Physiological
/ immunology
HbA1c
accelerator hypothesis
autoantibodies
plasma glucose
type 1 diabetes
β-cell stress
Journal
Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
22
06
2021
accepted:
19
07
2021
pubmed:
10
8
2021
medline:
4
2
2022
entrez:
9
8
2021
Statut:
ppublish
Résumé
The β-cell stress hypothesis suggests that increased insulin demand contributes to the development of type 1 diabetes. In the TRIGR trial we set out to assess the profile of plasma glucose and HbA1c before the diagnosis of clinical diabetes compared to nondiabetic children. A cohort of children (N = 2159) with an affected first-degree relative and increased HLA risk were recruited 2002-2007 and followed until 2017. To study the relationship between plasma glucose/HbA1c and the development of autoantibodies or clinical disease Kaplan-Meir curves were developed. Mixed models were constructed for plasma glucose and HbA1c separately. A family history of type 2 diabetes was related to an increase in plasma glucose (p < 0.001). An increase in glucose from the previous sample predicted clinical diabetes (p < 0.001) but not autoantibodies. An increase of HbA1c of 20% or 30% from the previous sample predicted the development of any autoantibody (p < 0.003 resp <0.001) and the development of diabetes (p < 0.002 resp <0.001. Participants without autoantibodies had lower HbA1c (mean 5.18%, STD 0.24; mean 33.08 mmol/mol, STD 2.85) than those who progressed to clinical disease (5.31%, 0.42; 34.46 mmol/mol, 4.68; p < 0.001) but higher than those who developed any autoantibody (5.10%, 0.30; 32.21 mmol/mol, 3.49; p < 0.001), or multiple autoantibodies (5.11%, 0.35; 32.26 mmol/mol, 3.92; p < 0.003). A pronounced increase in plasma glucose and HbA1c precedes development of clinical diabetes, while the association between plasma glucose or HbA1c and development of autoantibodies is complex. Increased insulin demand may contribute to development of type 1 diabetes.
Identifiants
pubmed: 34369627
doi: 10.1111/pedi.13251
pmc: PMC8530903
mid: NIHMS1729444
doi:
Substances chimiques
Autoantibodies
0
Blood Glucose
0
Glycated Hemoglobin A
0
HLA Antigens
0
Insulin
0
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
974-981Subventions
Organisme : NICHD NIH HHS
ID : U01 HD042444
Pays : United States
Organisme : NICHD NIH HHS
ID : U01 HD051997
Pays : United States
Organisme : NICHD NIH HHS
ID : U01 HD040364
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD051997
Pays : United States
Informations de copyright
© 2021 The Authors. Pediatric Diabetes published by John Wiley & Sons Ltd.
Références
Diabetes Care. 1995 Oct;18(10):1323-9
pubmed: 8721932
Diabetes Care. 1985 Sep-Oct;8 Suppl 1:10-6
pubmed: 3863753
Diabetes Care. 2013 Feb;36(2):348-54
pubmed: 23033245
Diabetologia. 2015 Aug;58(8):1787-96
pubmed: 25985749
Diabetes. 1989 Oct;38(10):1326-8
pubmed: 2676661
Diabetes Care. 2005 Feb;28(2):290-5
pubmed: 15677781
JAMA. 2018 Jan 2;319(1):38-48
pubmed: 29297078
Eur J Endocrinol. 2015 Feb;172(2):107-13
pubmed: 25378371
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693
Diabetes Care. 2012 Sep;35(9):1821-5
pubmed: 22699293
Br J Biomed Sci. 2009;66(4):208-15
pubmed: 20095132
Diabetologia. 2011 Mar;54(3):627-33
pubmed: 21153533
Science. 2016 Feb 12;351(6274):711-4
pubmed: 26912858
J Clin Endocrinol Metab. 2001 Oct;86(10):4782-8
pubmed: 11600541
Diabetologia. 2017 Aug;60(8):1467-1474
pubmed: 28526919
Diabetes. 2001 Nov;50(11):2444-50
pubmed: 11679420
Diabetologia. 1994 Jan;37(1):91-4
pubmed: 8150235
Diabetes. 2015 May;64(5):1719-27
pubmed: 25524912
JAMA. 2014 Jun 11;311(22):2279-87
pubmed: 24915259
Diabetes. 1995 Jun;44(6):652-7
pubmed: 7789630
Diabetologia. 1989 Feb;32(2):84-91
pubmed: 2656353
Clin Exp Immunol. 2012 Apr;168(1):5-11
pubmed: 22385231
Diabetes Care. 2005 Oct;28(10):2394-9
pubmed: 16186269
Diabetes Res Clin Pract. 2013 May;100(2):203-9
pubmed: 23529064
Lancet. 2016 Jun 4;387(10035):2340-2348
pubmed: 27302273
Diabetologia. 2001 Jul;44(7):914-22
pubmed: 11508279
Ann N Y Acad Sci. 2006 Oct;1079:374-82
pubmed: 17130582
Diabetologia. 2015 Jun;58(6):1188-97
pubmed: 25870022
JAMA. 2013 Jul 24;310(4):427-8
pubmed: 23917294